Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Other Accumulated Expenses (2020 - 2025)

Apellis Pharmaceuticals filings provide 6 years of Other Accumulated Expenses readings, the most recent being $2.7 million for Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses fell 7.87% year-over-year to $2.7 million, compared with a TTM value of $2.7 million through Dec 2025, down 7.87%, and an annual FY2025 reading of $2.7 million, down 7.87% over the prior year.
  • Other Accumulated Expenses hit $2.7 million in Q4 2025 for Apellis Pharmaceuticals, down from $4.7 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $30.8 million in Q3 2023, with the low at $2.7 million in Q4 2025.
  • Median Other Accumulated Expenses over the past 5 years was $14.0 million (2021), compared with a mean of $15.3 million.
  • The sharpest move saw Other Accumulated Expenses surged 256.4% in 2021, then plummeted 78.22% in 2025.
  • Year by year, Other Accumulated Expenses stood at $12.8 million in 2021, then rose by 7.88% to $13.8 million in 2022, then fell by 11.94% to $12.2 million in 2023, then plummeted by 75.56% to $3.0 million in 2024, then dropped by 7.87% to $2.7 million in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $2.7 million, $4.7 million, and $5.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.